6-week Safety and PD Study in Adults With NAFLD

• Status: Completed
• Trial end date: 2018-04-27
• Target enrollment: 0
• Participant gender: All

Summary

IN THIS PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, 3 ARM, PARALLEL- GROUP STUDY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS WILL BE ASSESSED IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• BMI at least 28 kg/m2

• Type 2 diabetes and/or metabolic syndrome

Exclusion Criteria:

• Liver disease

• Type 1 diabetes

• Recent heart attack or stroke

• Inability to have an MRI scan